Anti-Ki67 Antibody

1/2
Price:
Size:
Number:

Anti-Ki67 Antibody (Rabbit Polyclonal antibody) General Information

Product name
Anti-Ki67 Antibody
Validated applications
IHC-P
Species reactivity
Reacts with: Human
Specificity
Human Ki67
Immunogen
A synthetic peptide corresponding to the sequence of the Human Ki-67.
Preparation
Produced in rabbits immunized with purified, a synthetic peptide corresponding to the sequence of the Human Ki-67, and purified by antigen affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-Ki67 Antibody (Rabbit Polyclonal antibody) Validated Applications

Application Dilution
IHC-P 1:500-1:2000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-Ki67 Antibody (Rabbit Polyclonal antibody) Images

Immunochemical staining of Human ki-67 in human lung cancer with rabbit polyclonal antibody (1:1000, formalin-fixed paraffin embedded sections).
Immunochemical staining of Human ki-67 in human gastric cancer with rabbit polyclonal antibody (1:1000, formalin-fixed paraffin embedded sections).

Anti-Ki67 Antibody: Alternative Names

Anti-KIA Antibody; Anti-MIB- Antibody; Anti-MIB-1 Antibody; Anti-PPP1R105 Antibody

Ki67 Background Information

MKI67 contains 1 FHA domain and plays a key role in cell proliferation. During interphase, the MKI67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes. MKI67 protein is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells. MKI67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of MKI67-positive tumor cells is often correlated with the clinical course of cancer. It is also associated with ribosomal RNA transcription. Inactivation of antigen MKI67 leads to inhibition of ribosomal RNA synthesis.The MKI67 protein is a nuclear and nucleolar protein, which is tightly associated with somatic cell proliferation. Antibodies raised against the human MKI67 protein paved the way for the immunohistological assessment of cell proliferation, particularly useful in numerous studies on the prognostic value of cell growth in clinical samples of human neoplasms. MKI67 protein expression is an absolute requirement for progression through the cell-division cycle. Recently, MKI67 is proved be an independent prognostic factor for disease-free survival (HR 1.5-1.72) in multivariate analyses studies using samples from randomized clinical trials with secondary central analysis of the biomarker. MKI67 was not found to be predictive for long-term follow-up after chemotherapy. Nevertheless, high KI-67 was found to be associated with immediate pathological complete response in the neoadjuvant setting, with an LOE of II-B. MKI67 could be considered as a prognostic biomarker for therapeutic decision.

Full Name
marker of proliferation Ki-67
References
  • Rahmanzadeh R, et al. (2007) Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif. 40(3):422-30.
  • Bullwinkel J, et al. (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol. 206(3):624-35.
  • Schonk DM, et al. (1989) Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10. Hum Genet. 83(3):297-9.
  • Endl E, et al., 2000, Exp Cell Res. Jun 15;257(2): 231-7.
  • Luporsi E, et al., 2012, Breast Cancer Res Treat. 132(3): 895-915.
  • Scholzen T, et al., 2000, J Cell Physiol. 182(3): 311-22.
  • Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects
    Author
    Li, D;Xie, K;Zhang, L;Yao, X;Li, H;Xu, Q;Wang, X;Jiang, J;Fang, J;
    Year
    2016
    Journal
    Cancer Lett.
    Application
    IHC
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait